BHI News Section

• NARCAN® Naloxone HCl Nasal Spray 4 mg is currently the first and only prescription strength naloxone nasal spray to receive over-the-counter status in the U.S., which is a critical step toward broadening access
• Expected over-the-counter availability is anticipated by late summer of this year

GAITHERSBURG, Md., March 29, 2023 (GLOBE NEWSWIRE) — Today, Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has approved NARCAN® Naloxone HCl Nasal Spray 4 mg as an over-the-counter (OTC) emergency treatment of opioid overdose. This decision comes at a time when approximately every eight minutes, a person dies from an opioid overdose and research shows the epidemic is escalating in the U.S. with the rise in synthetic opioids. By offering NARCAN® Nasal Spray as an OTC treatment, anyone will be able to access it without a prescription, which is an important step in the fight to reduce the number of opioid overdose deaths occurring each day.

MARCH 28, 2023 – GAITHERSBURG, Md., (BUSINESS WIRE) — Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced it received $35 million in financing from China-based Shenzhen Salubris Pharmaceuticals Co., Ltd. The investment will be used to advance and accelerate lead candidate JK07, including the planned initiation of the first Phase 2 study in HFrEF, the continuation of the ongoing Phase 1b clinical trial in heart failure with preserved ejection fraction (HFpEF), and the launch of the Company’s first neurology clinical trial with JK07. The financing will also support the ongoing Phase 1/2 trial of JK08 in solid tumors and advance JK06, a pre-clinical biparatopic antibody-drug conjugate, into an initial Phase 1/2 study.

Leiden, the Netherlands , March 28, 2023 / B3C newswire / — MIMETAS, a global leader in human disease modeling announces that it has entered into a strategic partnership with Astellas Pharma Inc., a global pharmaceutical company. The partnership comprises utilizing MIMETAS’ comprehensive tumor models to support the next generation of immuno-oncological therapies.

Ready to explore the frontiers of cancer therapeutics? Discover how AUM Biosciences, with a key presence in Montgomery County, Maryland, in the BioHealth Capital Region, is revolutionizing the development of innovative oncology medicines and transforming the fight against cancer resistance. Join us on this episode of BioTalk with Rich Bendis as we chat with Vishal Doshi, Chairman & CEO of AUM Biosciences, a visionary leader in the biotech industry. Tune in to the conversation that’s sparking new hope in the battle against cancer.

Listen now via your favorite podcast platforms:
Apple – https://apple.co/42LvH4A Google – https://bit.ly/40yTOBC Spotify – https://spoti.fi/40F2NkV Amazon Music – https://amzn.to/40hFz4L TuneIn – https://bit.ly/42Gpfff YouTube – https://bit.ly/3TMIuji

ROCKVILLE, MD, March 22, 2023 (GLOBE NEWSWIRE) —  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported that following the U.S. Food and Drug Administration’s (FDA) approval of Incyte’s Biologics License Application (BLA) for ZYNYZ™ (retifanlimab-dlwr), the Company will receive a $15 million milestone payment from Incyte. ZYNYZ, a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), was previously developed by MacroGenics and licensed to Incyte pursuant to an exclusive global collaboration and license agreement in October 2017.

MARYLAND, March 23, 2023 — BioBuzz, the media outlet of Workforce Genetics, and the Frederick Innovative Technology Center, Inc. (FITCI) have announced a strategic partnership to fuel industry growth in the BioHealth Capital Region and growth for both parties.

FITCI CEO Kathie Callahan Brady says she is excited to move forward. “We both focus on the biotech space, but the perspective is different. It is exactly the type of collaboration we want to infuse into our new EDGE@321 entrepreneurial innovation center opening later this year, bridging competencies and markets to strengthen the whole community.”

Image: https://biobuzz.io

There has been a smoldering fire on the geopolitical stage that, if we continue to ignore, we risk allowing it to spread and burn its surrounding environment. I’m referring to the convergence of multiple technology revolutions with the high-stakes competition between the United States and a rising authoritarian competitor in China.

Event provides forum for researchers to learn more about ARPA-H’s Open Broad Agency Announcement

ARPA-H has opened its first Agency-wide Open BAA, seeking funding proposals for research aiming to improve health outcomes across patient populations, communities, diseases, and health conditions.

On April 4, ARPA-H will host a Proposers’ Day for interested parties to learn more about the application process for the Open BAA and ask questions. Register for the event. (Registration closes 5 p.m. ET on Monday, March 3)

MARYLAND, March 23, 2023 — BioBuzz, the media outlet of Workforce Genetics, and the Frederick Innovative Technology Center, Inc. (FITCI) have announced a strategic partnership to fuel industry growth in the BioHealth Capital Region and growth for both parties.

FITCI CEO Kathie Callahan Brady says she is excited to move forward. “We both focus on the biotech space, but the perspective is different. It is exactly the type of collaboration we want to infuse into our new EDGE@321 entrepreneurial innovation center opening later this year, bridging competencies and markets to strengthen the whole community.”